Semaglutide questions, answered from the data

What is semaglutide and how does it work?

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist — a peptide drug engineered from the human GLP-1 sequence with a one-week half-life^[17]. It binds and activates the GLP-1 receptor on pancreatic beta cells (where it increases glucose-dependent insulin secretion), on alpha cells (where it suppresses glucagon), on vagal afferents and in the gut (where it slows gastric emptying), and in the hypothalamus and hindbrain (where it reduces appetite)^[17]. The combination of these effects is why a single molecule lowers HbA1c, reduces body weight, lowers cardiovascular event rates, slows kidney function decline in CKD with diabetes, and resolves liver inflammation in MASH.

What kind of doctor prescribes semaglutide?

Several specialties are involved, depending on the indication:

• Endocrinologists — physicians subspecialized in endocrinology, diabetes, and metabolism — are the historical prescribers for the type 2 diabetes indication and the specialty most heavily represented among trial investigators.
• Obesity medicine physicians, certified by the American Board of Obesity Medicine (ABOM), manage anti-obesity pharmacotherapy as a primary discipline.
• Cardiologists are increasingly involved post-SELECT for cardiovascular risk reduction in patients with overweight or obesity and atherosclerotic CVD.
• Nephrologists are increasingly involved post-FLOW for chronic kidney disease in type 2 diabetes.
• Hepatologists and gastroenterologists are likely to take on a larger role following ESSENCE and the anticipated MASH approval.
• Primary care physicians (family medicine, internal medicine) actually write the majority of semaglutide prescriptions in the United States and are appropriate for uncomplicated cases.
• Nurse practitioners and physician assistants prescribe within their state's scope of practice, often in collaborative agreements.

What credentials should a semaglutide-prescribing provider have?

At a minimum, look for an active state medical license and board certification in the underlying specialty (Internal Medicine, Family Medicine, Pediatrics, or a relevant subspecialty). The most directly relevant subspecialty certifications are:

• ABIM subspecialty certification in Endocrinology, Diabetes and Metabolism — the standard for diabetes care.
• ABOM (American Board of Obesity Medicine) diplomate status — the standard for chronic weight management.
• FACE — Fellow of the American College of Endocrinology, awarded by AACE — for senior clinical endocrinology practice.

Beyond credentials, look for clinical experience with GLP-1 receptor agonist titration and side-effect management, and access to follow-up infrastructure: scheduled labs, weight tracking, cardiometabolic monitoring, and the ability to coordinate with adjacent specialties (e.g., ophthalmology if there is pre-existing diabetic retinopathy).

Can my primary care physician prescribe semaglutide, or do I need a specialist?

Most semaglutide prescriptions in the United States are written by primary care physicians, and that is appropriate for many patients with uncomplicated type 2 diabetes or uncomplicated obesity. Referral to an endocrinologist or obesity medicine specialist is more commonly considered when there is poorly controlled diabetes despite multiple agents, complex comorbidity (significant CKD, established CVD, pre-existing retinopathy, history of pancreatitis), pediatric or adolescent dosing, or unusual side-effect profiles requiring more nuanced titration. There is no FDA restriction on prescribing specialty — the labeling allows any licensed prescriber within their scope of practice.

Why does the ABIM and ABOM credentialing matter?

Board certification by the American Board of Internal Medicine (ABIM) in the Endocrinology, Diabetes and Metabolism subspecialty represents fellowship training plus a written exam covering hormonal and metabolic disease — including the pharmacology of GLP-1 receptor agonists, the management of diabetic complications, and the interpretation of trial endpoints. Similarly, ABOM certification in obesity medicine represents continuing education and an exam in the chronic-disease framework for obesity, anti-obesity pharmacotherapy, and the metabolic complications of weight gain and loss. Neither is legally required to prescribe semaglutide, but both signal that the prescriber has done formal study of the relevant disease biology and the drug class — which matters when a clinician is making titration, monitoring, and discontinuation decisions.

What about the principal investigators on the semaglutide trials?

The Phase 3 trials that built the semaglutide evidence base were conducted at academic medical centers and clinical research sites under principal investigators who are board-certified specialists. SUSTAIN-6 was led by endocrinologists including Marso, Bain, and Consoli^[1]. STEP 1 was led by endocrinologists including Wilding, Batterham, and Calanna^[2]. STEP TEENS was led by pediatric endocrinologists and specialists in pediatric obesity^[9]. SELECT was led by a cardiology-heavy steering committee including Lincoff, Brown-Frandsen, and Colhoun^[3]. FLOW was led by nephrologists Perkovic, Tuttle, and Rossing^[4]. ESSENCE was led by hepatologists Sanyal and Newsome^[11]. STEP-HFpEF was led by Kosiborod, Abildstrøm, and Borlaug — heart failure specialists^[10]. The investigators were typically board-certified in the specialty most relevant to the trial endpoint, which is one reason the trial program has been able to make claims across so many indications.

What FDA-approved indications does semaglutide have?

Five distinct indications: type 2 diabetes (glycemic control, subcutaneous and oral), chronic weight management in adults with BMI >=30 (or >=27 with a comorbidity), chronic weight management in adolescents 12+ with obesity, cardiovascular risk reduction in adults with overweight/obesity and established CVD (without diabetes), and reduced risk of kidney function worsening and CV death in adults with type 2 diabetes and chronic kidney disease. A MASH submission is under Priority Review following the ESSENCE Phase 3 results^[11].

How effective is semaglutide for weight loss in clinical trials?

In STEP 1, adults with obesity or overweight (no diabetes) on subcutaneous 2.4 mg weekly lost a mean −14.9% of body weight at 68 weeks vs −2.4% placebo; 86% achieved >=5% weight loss and 50% achieved >=15%^[2]. In STEP 5, that effect persisted through 104 weeks at −15.2%^[8]. In STEP TEENS, adolescents lost a mean −16.1% BMI^[9]. In SELECT (cardiovascular outcome trial in non-diabetic adults with CVD), the 4-year weight loss was sustained at −10.2%^[15]. Effect sizes are smaller in diabetes populations — typically 3.5–6.5 kg in the SUSTAIN program^[13].

What does the SELECT trial show?

SELECT randomized 17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes, to subcutaneous semaglutide 2.4 mg weekly or placebo. Over a mean ~40 months, the primary composite of CV death, nonfatal MI, or nonfatal stroke occurred in 6.5% of the semaglutide arm and 8.0% of placebo — a 20% relative risk reduction (HR 0.80, 95% CI 0.72–0.90, P<0.001). All-cause mortality favored semaglutide (HR 0.81). The trial drove the March 2024 FDA approval for cardiovascular risk reduction in obesity without diabetes^[3].

What does the FLOW trial show?

FLOW randomized 3,533 adults with type 2 diabetes and CKD (eGFR 25–75, with albuminuria) to subcutaneous semaglutide 1.0 mg weekly or placebo. Over a median 3.4 years, the composite of kidney failure, sustained >=50% eGFR decline, kidney death, or CV death was reduced by 24% (HR 0.76, 95% CI 0.66–0.88, P=0.0003). The trial was stopped early for efficacy. Subgroup analysis showed consistent CV benefit across all KDIGO risk strata^[4][16]. FDA approval for the kidney/CV-death indication followed in 2025.

What are the most common side effects?

The dominant adverse effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. They are typically mild-to-moderate and transient, peaking during dose titration. Nausea occurs in roughly 20% of patients at the 0.5–1.0 mg weekly dose and up to roughly 44% at the 2.4 mg weekly weight-management dose. Cholelithiasis and cholecystitis are increased — roughly 2.6% vs 1.2% placebo in STEP 1 — likely related to the speed of weight loss and gallbladder motility effects^[19]. Injection-site reactions are uncommon and generally mild.

Is semaglutide associated with thyroid cancer or pancreatitis?

Human data have not shown an increase in thyroid cancer, and a systematic review found thyroid cancer incidence <1% in semaglutide users with no significant excess vs placebo^[18]. Acute pancreatitis is a class warning; meta-analytic incidence is approximately 0.24%, not significantly elevated vs comparators^[18]. The prescribing information recommends discontinuing if pancreatitis is suspected.

Why is semaglutide given as a once-weekly injection?

Because the molecular engineering enables it. Native human GLP-1 has a half-life of about two minutes — DPP-4 cleaves it almost immediately. Semaglutide carries two modifications that change this: an Aib substitution at position 8 that blocks DPP-4 cleavage, and a C-18 fatty di-acid side chain that drives >99% albumin binding. The result is a circulating half-life of approximately 165–184 hours — about one week — which is what makes a once-weekly subcutaneous schedule feasible^[17].

How is oral semaglutide different from injectable?

It is the same molecule, but co-formulated with the absorption enhancer SNAC to enable intestinal uptake. Oral bioavailability is 0.4–1% (vs 89% subcutaneous), so doses are larger (3/7/14 mg daily vs 0.25–2.4 mg weekly). Oral dosing requires fasting administration with minimal water and a 30-minute wait before food or other oral medications^[5]. Efficacy is comparable for HbA1c reduction at the 14 mg daily dose; PIONEER PLUS demonstrated that higher oral doses (25 mg, 50 mg) produce larger reductions^[20].

What is the difference between semaglutide for diabetes and for weight management?

Same molecule, different maintenance dose. Type 2 diabetes uses 0.5 mg, 1.0 mg, or 2.0 mg weekly subcutaneously, or 3/7/14 mg daily orally. Chronic weight management uses 2.4 mg weekly subcutaneously after a 16-week titration. The cardiovascular outcome benefit in adults without diabetes (SELECT) was demonstrated at the 2.4 mg weight-management dose^[3], while the diabetes cardiovascular benefit (SUSTAIN-6) was demonstrated at 0.5 mg and 1.0 mg^[1]. The kidney benefit (FLOW) was at 1.0 mg^[4].

What happens if I stop taking semaglutide?

The STEP 1 trial extension followed 327 participants for 52 weeks after a 68-week treatment phase. The semaglutide arm regained a mean 11.6 percentage points of weight, leaving net weight loss from baseline at week 120 of 5.6% (semaglutide) vs 0.1% (placebo). 48.2% of the semaglutide arm maintained >=5% loss^[14]. The pattern — approximately two-thirds of weight loss regained within a year of discontinuation — is consistent with the chronic-disease framing of obesity that the major endocrinology and obesity-medicine societies use to advocate for long-term treatment.

Is semaglutide safe in adolescents and at what age?

Semaglutide is FDA-approved for chronic weight management in adolescents aged 12 and older with obesity (BMI at or above the 95th percentile), based on the STEP TEENS trial of 201 adolescents. Mean BMI change at 68 weeks was −16.1% for semaglutide vs +0.6% for placebo; 73% of the semaglutide arm achieved >=5% weight loss, and approximately 45% dropped below the BMI cutoff for clinical obesity^[9]. As with adults, the most common adverse effects were gastrointestinal.